Valneva’s registered office is located at 12 TER Quai Perrache, 69002 Lyon, France.
Valneva has been listed on Euronext Paris under the symbol VLA since May 2013 and on Nasdaq under the symbol VALN since May 6, 2021.
Valneva’s fiscal year-end is December 31.
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The Company focuses on vaccines that can make a difference, where there is opportunity to be first-, only-, or best-in-class. Valneva currently markets three proprietary vaccines, whose revenues help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced tetravalent Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. Valneva’s vision is to contribute to a world where no one dies or suffers from a vaccine-preventable disease.
A prophylactic vaccine is a biological substance designed to stimulate the immune system and prevent the onset of infectious diseases. This approach has been instrumental in controlling or even eradicating many diseases, such as smallpox and polio.
Valneva leverages expertise across multiple proven vaccine platforms, selecting the technology best suited to address each targeted disease. The Company’s commercial portfolio comprises three differentiated products:
IXIARO® is the only Japanese encephalitis vaccine approved in the U.S. and Europe.
IXCHIQ® was the first approved single-shot chikungunya vaccine (EMA website).
DUKORAL® is the only cholera and ETEC (Enterotoxigenic Escherichia coli) vaccine approved.
Please visit the Products Page on Valneva’s website for more information about the Company’s commercial products.
In R&D, Valneva strives to develop first-, best-, or only-in-class vaccine candidates that address unmet infectious disease needs, with the objective of bringing them to market either on our own or through partnerships.
Our pipeline consists of assets at all stages of research & development and includes the only Lyme disease vaccine candidate (VLA15) in advanced clinical development, which we are developing in partnership with Pfizer, as well as the world’s most clinically advanced tetravalent Shigella vaccine candidate, in collaboration with LimmaTech Biologics AG (“LimmaTech”), and proprietary vaccine candidates against other global public health threats.
Valneva operates an integrated business model that spans the entire vaccine lifecycle. This includes research and development (R&D), manufacturing, and commercialization. By leveraging its proven development capabilities, Valneva rapidly advances late-stage clinical programs, ensuring a seamless transition from regulatory approval to market entry. Valneva’s hybrid strategy is to drive commercial growth and revenues while continuing to invest in R&D to build continual shareholder value.
Valneva commercializes its vaccines through a combination of direct commercial activities and strategic partnerships in selected markets. As an example, in Germany, CSL Seqirus has secured exclusive marketing and distribution rights of Valneva’s three proprietary vaccines, including IXCHIQ®, IXIARO®, and DUKORAL®.
Please refer to the dedicated ESG section of Valneva’s website (Link) to find information about Valneva’s CSR activities.
- Shareholders can access the following documents:
These documents are available in the Investor and Media section of Valneva’s website.
Yes, Valneva is SRD eligible under the Long-Only option. The deposit requirement for SRD operations varies; please consult your financial institution for specific details.
Yes, Valneva shares are eligible for inclusion in a PEA-PME account, making it an attractive investment for individual investors under the French tax framework. Investors should consult their financial and tax advisors regarding the suitability and tax treatment of any investment.
Detailed financial information is available in the annual reports, including the 20-F and Unified Registered Document, and in financial presentations in the Investor section of Valneva’s website.
Key elements of Valneva’s investment proposition include:
- Established commercial business with revenues generated by three proprietary vaccines.
- A blockbuster opportunity with the only Lyme disease vaccine candidate in advanced clinical development, partnered with Pfizer. Regulatory submission was validated by the European Medicines Agency and submission to the U.S. Food and Drug Administration is expected before the end of the year.
- Potential for financial self-sustainability starting in 2027, subject to successful regulatory approval and commercialization of its Lyme disease vaccine.
- Proven vaccine development and manufacturing capabilities, spanning research, development, production, and commercialization.
Valneva shares can be purchased through most banks, brokers, and investment platforms. The Company’s ordinary shares are listed on Euronext Paris under the ticker symbol VLA (ISIN: FR0004056851), and its American Depositary Shares (ADSs) are listed on Nasdaq under the ticker symbol VALN.
- Bearer shares: Shares are purchased and held in a securities account with a bank or broker. The shareholder’s identity is generally not known directly by the Company.
- Registered shares: Shares are registered in the shareholder’s name in the Company’s share register, providing direct communication and invitations to General Meetings.
To become a registered shareholder, contact your broker or financial institution to transfer and register your shares with Valneva. Registered ownership offers advantages like automatic updates and direct participation in General Meetings.
Subscribe to financial updates on Valneva’s Investor Relations page or visit the section for financial reports, press releases, and other key information.
For direct inquiries, email Valneva’s Investor Relations team: investors@valneva.com
Information regarding Valneva’s share capital, including the number of ordinary shares listed on Euronext Paris and American Depositary Shares (ADS), is available on the Shareholder Structure page of Valneva’s website (Link).
Information regarding Valneva’s share capital transactions, including capital increases and other share-related transactions, is available in the Regulated Information section of Valneva’s website (Link), under Share Capital Transactions.
Valneva is followed by a number of financial analysts from leading investment banks and brokerage firms. A list of analysts currently covering the Company, together with their respective institutions, is available in the Investor Relations section of Valneva’s website (Link).
Please note that any opinions, estimates, forecasts, or recommendations regarding Valneva’s performance are solely those of the analysts concerned and do not represent the views of the Company.
Information on Valneva’s share price, historical trading data, market capitalization, and trading volumes is available in the Share Information section of Valneva’s Investor Relations website. Investors can also access real-time or delayed stock price information through financial market platforms covering Valneva’s ordinary shares listed on Euronext Paris (ticker: VLA) and its American Depositary Shares (ADSs) listed on Nasdaq (ticker: VALN).
The key dates for shareholders, including financial results announcements and General Meetings, are regularly updated on the Events page in the Investors section of Valneva’s website.
Shareholders can attend the General Meeting by obtaining an entrance card:
- Registered shareholders: Entrance cards are sent automatically
- Bearer shareholders: Request a certificate of participation from your financial institution
If you are unable to attend the General Meeting in person, you may still exercise your voting rights by:
- Voting remotely before the meeting, either electronically or by mail, as described in the meeting notice.
- Granting a proxy to a person of your choice to vote on your behalf.
- Giving a proxy to the Chair of the General Meeting.
Detailed instructions, deadlines, and voting procedures are provided in the notice of meeting and related documentation made available in advance of each General Meeting on the Company’s investor relations website.
Valneva’s Statutory Auditors are PricewaterhouseCoopers and Deloitte & Associés.
All SEC filings of Valneva can be found via this link https://valneva.com/investors/sec-filings
For any investor-related questions, please contact Valneva’s Investor Relations team at investors@valneva.com.
To receive email updates, please subscribe via this link: Subscribe to Valneva News